Details of the Drug Reposition

General Information of This Drug (ID: DMT5GNL)

Drug Name
Romidepsin   DMT5GNL
Synonyms
Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
9 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Primary cutaneous T-cell lymphoma DIS35WVW N.A. Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified DIS5OHQF N.A. Approved [1]
Lung carcinoid tumor DISH3GHR N.A. Approved [1]
Glucagonoma DISDU90K N.A. Approved [1]
Gastrin-producing neuroendocrine tumor DIS8TYKO N.A. Approved [1]
Cutaneous T-cell lymphoma DISAYSZB 2B01 Approved [2]
Insulinoma DISIU1JS 2C10.1 Approved [1]
Melanoma DIS1RRCY 2C30 Approved [1]
Urethral cancer DISDWYSE 2C93 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Indications(s)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Peripheral T-cell lymphoma DISCDT4E 2A90.C Phase 3 [3]
Renal cell carcinoma DISQZ2X8 2C90 Phase 3 [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Upper tract urothelial carcinoma DISTE2ZH N.A. Discontinued in Phase 3 [4]
------------------------------------------------------------------------------------

References

1 Romidepsin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 The Study of Nasonex Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)